Tashkent, Uzbekistan (UzDaily.com) -- The international company STADA Arzneimittel AG, one of the largest pharmaceutical companies in Europe, has registered the IP LLC STADA subsidiary in Uzbekistan. The company plans to expand the supply of quality medicines to the domestic market, as well as increase its contribution to strengthening the country’s healthcare system.

“Uzbekistan plays an important role in expanding STADA’s business in the region, showing growth potential with a population of more than 35 million people and a government policy in the field of healthcare development,” said Arminas Macevicius, STADA Vice President in the Eurasia Region. We welcome the approach when the state invests in people’s health: over the past years, cardinal changes have been carried out aimed at increasing the accessibility of high-quality and effective medical care to the population.

Currently, the Ministry of Health of Uzbekistan is engaged in the digitalization of healthcare, the development of medical insurance and medical clusters. This attracts investors, and investments in the pharmaceutical industry are not only about money and the labor market, but also about technology, knowledge and experience. And STADA sees its mission as providing healthcare professionals and the medical community in Uzbekistan with data they can trust to make informed decisions about public health.”

For 10 months of last year, the growth of the pharmaceutical market of the Republic of Uzbekistan amounted to 10.6% in monetary terms (in euros, according to IQVIA). STADA believes that the market will grow rapidly as the country’s healthcare infrastructure improves and insurance medicine is introduced. “According to our forecasts, the market for medicines in packages will grow this year by 12-15% compared to 2022,” says Bakhtiyor Khadjimukhamedov, head of the STADA representative office in Uzbekistan. We predict a significant increase in vitamins and dietary supplements. We should also expect growth in the hospital sector, as the government pays serious attention to providing the healthcare system with the full range of necessary medicines. And first of all, these are medicines for the treatment of oncological diseases, diabetes mellitus and rare diseases. It is also important that the procedure for accelerated registration of drugs from developed countries, the registration of which we trust, has been introduced - this will also affect the growth of the market.”

STADA has already registered several drugs in Uzbekistan for the treatment of urological, neurological and cardiovascular diseases. In the near future, the possibility of registering oncological drugs is being considered.

STADA became the first international pharmaceutical company to produce products labeled with identification tools for the Uzbek market. The topical hemostatic agent Natalsid was chosen as the first drug to participate in the pilot project. Work on the national digital labeling project was launched in February last year with the participation of the regulator and other market participants. The introduction of a system for monitoring the movement of medicines will make the domestic pharmaceutical market transparent and safe in terms of combating counterfeit and counterfeit goods.

Hovsep Voskanyan, Head of the German Economy Representative Office in Central Asia, expressed his satisfaction with the expansion of STADA’s business. “We are pleased with the strengthening of German business in Uzbekistan and the region as a whole. STADA is one of the important participants in the development of the German-Uzbek economic cooperation. We support the company’s efforts to develop a modern model of medicine in the country,” he said.